Welcome to LookChem.com Sign In|Join Free

CAS

  • or

22204-53-1

Post Buying Request

22204-53-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

22204-53-1 Usage

Non-steroidal anti-inflammatory drugs

Naproxen is a non-steroidal anti-inflammatory drug ,it is a PG synthase inhibitor, which can inhibit prostaglandin synthetase, it has significant analgesic and antipyretic effects, oral absorption is rapid and complete, 2 to 4 hours after a dose ,plasma concentration reaches the peak, in the blood , more than 99% is bound to plasma proteins, t1/2 is 13 to 14 hours, about 95% is discharged from the urine with the prototype and metabolites.it is clinically used For the treatment of rheumatic and rheumatoid arthritis , osteoarthritis, ankylosing spondylitis, gout, arthritis, tenosynovitis.it can also be used to alleviate pain caused by musculoskeletal sprains, contusions,damages and dysmenorrhea . But it should be noted that like other non-steroidal anti-inflammatory drugs, the same serious gastrointestinal adverse reactions could occur at any time while taking naproxen during treatment, so the active gastroduodenal ulcer patients are hanged, other gastrointestinal tract disease patients should take this drug under close medical supervision. The above information is edited by the lookchem of Tian Ye.

Chemical Properties

Different sources of media describe the Chemical Properties of 22204-53-1 differently. You can refer to the following data:
1. White crystal or crystalline powder. Melting point 155.3 ℃. Soluble in acetone, soluble in methanol, ethanol, acetic acid, insoluble in benzene, practically insoluble in water. In case of light,it is color-graded, odorless, tasteless.
2. white to light yellow crystal powde

Uses

Different sources of media describe the Uses of 22204-53-1 differently. You can refer to the following data:
1. It is a non-steroidal anti-inflammatory drug for the relief of fever and inflammation and pain associated with arthritis or other symptoms , it has anti-inflammatory, antipyretic and analgesic effects. Naproxen plays a role by inhibiting the cyclooxygenase, which generates prostaglandin and is one kind of enzymes related to inflammatory mediators . It is recommended to take the drug during meals to reduce stomach irritation.
2. An anti-inflammatory, analgesic, antipyretic. A non-steroidal anti-inflammatory
3. (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid is a non-selective cyclooxygenase (COX-1 and COX-2) inhibitor.
4. Being analogous to other drugs of this series, naproxene exhibits analgesic, fever-reducing, and long-lasting anti-inflammatory action. It causes reduction and removal of painful symptoms including joint pain, stiffness, and swelling in the joints. It is used in the same indications as ibuprofen.

Used in Particular Diseases

Acute Gouty Arthritis: Dosage and Frequency:?500 mg twice daily for 3 days, then 250–500 mg daily for 4–7 days

production method

by methylation, acetylation With 2-naphthol , 6-methoxy-2-acetonaphthone is produced, then it is condensed with acid ester, then generate the product through isomerization, hydrolysis, oxidation, and split and other reactions.

Category

Toxic substances

Toxicity grading

Highly toxic

Acute toxicity

Oral-rat LD50 248 mg/kg; Oral-Mouse LD50: 360 mg/kg

Flammability and hazard characteristics

Combustible; combustion produces toxic and acrid smoke.

Storage Characteristics

Ventilated, low-temperature ,dry storeroom, it should be stored and transported from food raw materials separately.

Extinguishing agent

Water, dry powder, foam,sand

Description

Naproxen is synthesized from 2-methoxynaphthalene and the (+)-isomer obtained by resolution with cinchonidine (61). It was introduced in the United States in 1976 and, as a generic drug, has consistently been among the more popular NSAIDs. It is marketed as the S-(+)-enantiomer, but interestingly, the sodium salt of the (–)-isomer also is on the market as Anaprox. As an inhibitor of prostaglandin biosynthesis, it is 12 times more potent than aspirin, 10 times more potent than phenylbutazone, three to four times more potent than ibuprofen, and four times times more potent than fenoprofen, but it is approximately 300 times less potent than indomethacin.

Originator

Naprosyn,Syntex,UK,1973

Definition

ChEBI: A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such a osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.

Indications

Naproxen (Naprosyn) also has pharmacological properties and clinical uses similar to those of ibuprofen. It exhibits approximately equal selectivity for COX-1 and COX-2 and is better tolerated than certain NSAIDs, such as indomethacin. Adverse reactions related to the GI tract occur in about 14% of all patients, and severe GI bleeding has been reported. CNS complaints (headache, dizziness, drowsiness), dermatological effects (pruritus, skin eruptions, echinoses), tinnitus, edema, and dyspnea also occur.

Manufacturing Process

According to US Patent 3,658,858, a solution of 24 grams of 2-bromo-6- methoxynaphthalene in 300 ml of tetrahydrofuran is slowly added to 2.5 grams of magnesium turnings and 100 ml of tetrahydrofuran at reflux temperature. After the addition is complete, 20 grams of cadium chloride is added, and the resultant mixture is refluxed for 10 minutes to yield a solution of di-(6-methoxy-2-naphthyl)cadmium (which can be separated by conventional chromatography, although separation is unnecessary).A solution of 18 grams of ethyl 2-bromopropionate in 20 ml of tetrahydrofuran is then added to the cooled reaction mixture. After 24 hours at 20°C, the product is hydrolyzed by adding 200 ml of 5 weight percent methanolic sodium hydroxide followed by heating to reflux for 1 hour. The reaction mixture is then diluted with excess 1 N sulfuric acid and extracted with ether. The ether phase is separated, evaporated to dryness and the residue is recrystallized from acetone-hexane to yield 2-(6-methoxy-2- naphthyl)propionic acid.

Brand name

Naprosyn (Roche).

Therapeutic Function

Antiinflammatory

Synthesis Reference(s)

Tetrahedron, 49, p. 8433, 1993 DOI: 10.1016/S0040-4020(01)81926-8

General Description

Naproxen (Naprosyn, Anaprox), marketed as the (S)-enantiomer,is well absorbed after oral administration, givingpeak plasma levels in 2 to 4 hours and a half-life of 13 hours.Naproxen is highly protein bound and displaces most protein-bound drugs. It is recommended for use in RA, OA, acute gouty inflammation, and in primary dysmenorrhea. Itshows good analgesic activity (i.e., 400 mg is comparable to75–150 mg of oral meperidine and superior to 65 mg ofpropoxyphene and 325 mg of aspirin plus 30 mg of codeine).It is also available OTC as 200-mg tablets (Aleve).

Pharmacokinetics

Naproxen is almost completely absorbed following oral administration. Peak plasma levels are achieved within 2 to 4 hours following administration. Like most of the acidic NSAIDs (pKa = 4.2), it is highly bound (99.6%) to plasma proteins. Approximately 70% of an administered dose is eliminated as either unchanged drug (60%) or as conjugates of unchanged drug (10%). The remainder is converted to the 6-O-desmethyl metabolite by both CYP3A4 and CYP1A2 and, further, to the glucuronide conjugate of the demethylated metabolite. The 6-O-desmethyl metabolite lacks anti-inflammatory activity. Like most of the arylalkanoic acids, the most common side effect associated with the use of naproxen is irritation to the GI tract. The most common other adverse reactions are associated with CNS disturbances (e.g., nausea and dizziness).

Clinical Use

Naproxen is indicated for the treatment of rheumatoid arthritis, osteoarthritis, juvenile arthritis, ankylosing spondylitis, tendinitis, bursitis, acute gout, and primary dysmenorrhea and for the relief of mild to moderate pain.

Synthesis

Naproxene, 2-(6-methoxy-2-naphthyl)-propionic acid (3.2.15) can be synthesized by the methods of synthesis described for ibuprofen as well as by the methods of fenoprofen (3.2.21) and ketoprofen (3.2.27) synthesis that will be described below from 2-acetyl or 2-chloromethyl-6-methoxynaphthaline [99–101].

Veterinary Drugs and Treatments

The manufacturer lists the following indications: “…for the relief of inflammation and associated pain and lameness exhibited with myositis and other soft tissue diseases of the musculoskeletal system of the horse.” (Package Insert; Equiproxen?—Syntex). It has also been used as an antiinflammatory/analgesic in dogs for the treatment of osteoarthritis and other musculoskeletal inflammatory diseases (see adverse reactions below).

Drug interactions

Potentially hazardous interactions with other drugs ACE inhibitors and angiotensin-II antagonists: antagonism of hypotensive effect; increased risk of nephrotoxicity and hyperkalaemia. Analgesics: avoid concomitant use of 2 or more NSAIDs, including aspirin (increased side effects); avoid with ketorolac (increased risk of side effects and haemorrhage). Antibacterials: possibly increased risk of convulsions with quinolones. Anticoagulants: effects of coumarins and phenindione enhanced; possibly increased risk of bleeding with heparins, dabigatran and edoxaban - avoid long term use with edoxaban. Antidepressants: increased risk of bleeding with SSRIs and venlaflaxine. Antidiabetic agents: effects of sulphonylureas enhanced. Antiepileptics: possibly increased phenytoin concentration. Antivirals: increased risk of haematological toxicity with zidovudine; concentration possibly increased by ritonavir. Ciclosporin: may potentiate nephrotoxicity Cytotoxics: reduced excretion of methotrexate; increased risk of bleeding with erlotinib. Diuretics: increased risk of nephrotoxicity; antagonism of diuretic effect; hyperkalaemia with potassium-sparing diuretics. Lithium: excretion decreased. Pentoxifylline: increased risk of bleeding. Probenecid: excretion reduced by probenecid. Tacrolimus: increased risk of nephrotoxicity.

Metabolism

Naproxen is extensively metabolised in the liver to 6-0-desmethyl naproxen. Both naproxen and 6-0-desmethyl naproxen are further metabolised to their respective acylglucuronide conjugated metabolites. About 95% of a dose is excreted in urine as naproxen and 6-O-desmethylnaproxen and their conjugates. Less than 5% of a dose appears in the faeces.

references

[1] barnett j, chow j, ives d, et al. purification, characterization and selective inhibition of human prostaglandin g/h synthase 1 and 2 expressed in the baculovirus system[j]. biochimica et biophysica acta (bba)-protein structure and molecular enzymology, 1994, 1209(1): 130-139.[2] laneuville o, breuer d k, dewitt d l, et al. differential inhibition of human prostaglandin endoperoxide h synthases-1 and-2 by nonsteroidal anti-inflammatory drugs[j]. journal of pharmacology and experimental therapeutics, 1994, 271(2): 927-934.[3] dubois r n, abramson s b, crofford l, et al. cyclooxygenase in biology and disease[j]. the faseb journal, 1998, 12(12): 1063-1073.[4] agdeppa e d, kepe v, petri a, et al. in vitro detection of (s)-naproxen and ibuprofen binding to plaques in the alzheimer’s brain using the positron emission tomography molecular imaging probe 2-(1-{6-[(2-[18 f] fluoroethyl)(methyl) amino]-2-naphthyl} ethylidene) malononitrile[j]. neuroscience, 2003, 117(3): 723-730.

Check Digit Verification of cas no

The CAS Registry Mumber 22204-53-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,2,2,0 and 4 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 22204-53:
(7*2)+(6*2)+(5*2)+(4*0)+(3*4)+(2*5)+(1*3)=61
61 % 10 = 1
So 22204-53-1 is a valid CAS Registry Number.
InChI:InChI=1/C14H14O3/c1-9(14(15)16)10-3-4-12-8-13(17-2)6-5-11(12)7-10/h3-9H,1-2H3,(H,15,16)/p-1/t9-/m0/s1

22204-53-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (M1021)  (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic Acid  >99.0%(GC)(T)

  • 22204-53-1

  • 25g

  • 790.00CNY

  • Detail
  • TCI America

  • (M1021)  (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic Acid  >99.0%(GC)(T)

  • 22204-53-1

  • 500g

  • 5,500.00CNY

  • Detail
  • Alfa Aesar

  • (L09855)  (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid, 99%   

  • 22204-53-1

  • 1g

  • 279.0CNY

  • Detail
  • Alfa Aesar

  • (L09855)  (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid, 99%   

  • 22204-53-1

  • 5g

  • 946.0CNY

  • Detail
  • Alfa Aesar

  • (L09855)  (S)-(+)-2-(6-Methoxy-2-naphthyl)propionic acid, 99%   

  • 22204-53-1

  • 25g

  • 3312.0CNY

  • Detail
  • Sigma-Aldrich

  • (PHR1040)  Naproxen  pharmaceutical secondary standard; traceable to USP, PhEur and BP

  • 22204-53-1

  • PHR1040-500MG

  • 878.44CNY

  • Detail
  • Sigma-Aldrich

  • (N0250000)  Naproxen  European Pharmacopoeia (EP) Reference Standard

  • 22204-53-1

  • N0250000

  • 1,880.19CNY

  • Detail
  • USP

  • (1457301)  Naproxen  United States Pharmacopeia (USP) Reference Standard

  • 22204-53-1

  • 1457301-200MG

  • 4,662.45CNY

  • Detail
  • Sigma-Aldrich

  • (46482)  Naproxen  VETRANAL, analytical standard

  • 22204-53-1

  • 46482-250MG

  • 675.09CNY

  • Detail
  • Aldrich

  • (284785)  (S)-(+)-6-Methoxy-α-methyl-2-naphthaleneaceticacid  98%

  • 22204-53-1

  • 284785-5G

  • 398.97CNY

  • Detail
  • Aldrich

  • (284785)  (S)-(+)-6-Methoxy-α-methyl-2-naphthaleneaceticacid  98%

  • 22204-53-1

  • 284785-25G

  • 1,392.30CNY

  • Detail

22204-53-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name naproxen

1.2 Other means of identification

Product number -
Other names (S)-(+)-6-Methoxy-α-methyl-2-naphthaleneacetic Acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:22204-53-1 SDS

22204-53-1Synthetic route

(R)-praziquanacetamide (S)-naproxen salt

(R)-praziquanacetamide (S)-naproxen salt

A

(R)-praziquanacetamide hydrochloride

(R)-praziquanacetamide hydrochloride

B

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With hydrogenchloride In waterA 100%
B n/a
naproxen
23981-80-8

naproxen

A

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

B

(R)-2-(6-methoxy-2-naphthyl)propionic acid
23979-41-1

(R)-2-(6-methoxy-2-naphthyl)propionic acid

Conditions
ConditionsYield
With 1-deoxy-1-(octylamino)-d-glucitol In acetonitrile for 6h; Heating;A 99%
B n/a
With phosphate buffer; sodium dodecyl-sulfate; vancomycin at 20℃; Product distribution; electrophoretic enantioseparations, various substrates;
With ammonium acetate Purification / work up; Resolution of racemate;
toluene-MeOH

toluene-MeOH

2-(6-methoxynaphth-2-yl)acrylic acid
27602-79-5

2-(6-methoxynaphth-2-yl)acrylic acid

pyrographite
7440-44-0

pyrographite

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With triethylamine98%
Naprelan
26159-34-2

Naprelan

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With hydrogenchloride In methanol at 20℃;98%
With hydrogenchloride In water pH=< 2; Inert atmosphere;94.3%
(R)-praziquanammonium (S)-2-(6-methoxy-naphthalen-2-yl)-propionate

(R)-praziquanammonium (S)-2-(6-methoxy-naphthalen-2-yl)-propionate

A

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

B

(R)-(-)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one
55375-92-3

(R)-(-)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one

Conditions
ConditionsYield
With hydrogenchloride In water at 20℃; for 0.5h; pH=1;A 97.9%
B n/a
2-(6-methoxynaphth-2-yl)acrylic acid
27602-79-5

2-(6-methoxynaphth-2-yl)acrylic acid

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With C48H50Cl4N2O2P2Ru3; hydrogen; sodium hydrogencarbonate In methanol at 20℃; under 3750.38 Torr; for 24h; Autoclave; enantioselective reaction;97%
With hydrogen; (S)-Ru(OAc)2-BINAP In methanol at 15 - 30℃; under 102600 Torr; for 12h;92%
With C42H48CoP2; hydrogen; triethylamine; zinc In methanol at 50℃; under 25858.1 Torr; for 16h; enantioselective reaction;91%
2-(1-bromoethyl)-2-(6-methoxylnaphth-2-yl)-5,5-dimethyl-1,3-epoxyhexane

2-(1-bromoethyl)-2-(6-methoxylnaphth-2-yl)-5,5-dimethyl-1,3-epoxyhexane

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
Stage #1: 2-(1-bromoethyl)-2-(6-methoxylnaphth-2-yl)-5,5-dimethyl-1,3-epoxyhexane With zinc 2-(6-methoxylnaphthyl)propionate In toluene for 5.5h; Reflux;
Stage #2: With sodium hydroxide In toluene for 3.5h; Reflux;
Stage #3: With water; pyrographite In toluene for 0.5h; Reflux;
96.9%
(S)-3-methyl-2-phenylbutylammonium (S)-2-(6-methoxy-2-naphthyl)propionate

(S)-3-methyl-2-phenylbutylammonium (S)-2-(6-methoxy-2-naphthyl)propionate

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With sodium hydroxide In water96.3%
6-methoxy-2-naphthylacetic acid
23981-47-7

6-methoxy-2-naphthylacetic acid

methyl iodide
74-88-4

methyl iodide

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
Stage #1: 6-methoxy-2-naphthylacetic acid With n-butyllithium; N1,N3-bis((R)-1-phenyl-2-(piperidin-1-yl)ethyl)propane-1,3-diamine In tetrahydrofuran; hexanes at 0℃; Inert atmosphere;
Stage #2: methyl iodide In tetrahydrofuran; hexanes at -90℃; for 0.0333333h; Inert atmosphere; optical yield given as %ee; enantioselective reaction;
96%
Stage #1: 6-methoxy-2-naphthylacetic acid With n-butyllithium; N1,N3-bis((R)-1-phenyl-2-(piperidin-1-yl)ethyl)propane-1,3-diamine In tetrahydrofuran; hexane at -78 - 0℃; for 0.333333h; Inert atmosphere;
Stage #2: methyl iodide In tetrahydrofuran; hexane at -78℃; for 0.0333333h; Inert atmosphere; enantioselective reaction;
94%
S-2-(6-methoxy-2-naphthyl)propionaldehyde
32305-59-2

S-2-(6-methoxy-2-naphthyl)propionaldehyde

2-pentene
109-68-2

2-pentene

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With sodium dihydrogenphosphate; sodium chlorite In water at 20℃; for 1h;96%
(S)-2-(6-methoxynaphthalen-2-yl)-N-phenylpropanamide

(S)-2-(6-methoxynaphthalen-2-yl)-N-phenylpropanamide

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With sulfuric acid In 1,4-dioxane; water at 80℃; for 8h;96%
2-(6-Methoxy-naphthalen-2-yl)-2-methyl-malonic acid
126899-42-1

2-(6-Methoxy-naphthalen-2-yl)-2-methyl-malonic acid

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With tris hydrochloride In water at 37℃; for 24h; pH=7.0; Reagent/catalyst; Enzymatic reaction; enantioselective reaction;95%
(S)-3-(2-(6-methoxynaphthalen-2-yl)propanoyl)oxazolidin-2-one
1330660-68-8

(S)-3-(2-(6-methoxynaphthalen-2-yl)propanoyl)oxazolidin-2-one

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With water; dihydrogen peroxide; lithium hydroxide In tetrahydrofuran at 20℃; for 12h;94%
Stage #1: (S)-3-(2-(6-methoxynaphthalen-2-yl)propanoyl)oxazolidin-2-one With lithium hydroxide monohydrate In tetrahydrofuran; water at 20℃; for 3h;
Stage #2: With hydrogenchloride In tetrahydrofuran; water pH=4;
Ru((-)-T-BINAP)(O2 CCF3)2

Ru((-)-T-BINAP)(O2 CCF3)2

2-(6-methoxynaphth-2-yl)acrylic acid
27602-79-5

2-(6-methoxynaphth-2-yl)acrylic acid

argon

argon

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
In methanol93.7%
tert-butyl trimethylsilyl methyl ketene acetal
72658-10-7

tert-butyl trimethylsilyl methyl ketene acetal

6-methoxynaphthalen-2-yl trifluoromethanesulfonate
129731-74-4

6-methoxynaphthalen-2-yl trifluoromethanesulfonate

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
Stage #1: tert-butyl trimethylsilyl methyl ketene acetal; 6-methoxynaphthalen-2-yl trifluoromethanesulfonate With (R)-2-(dicyclohexylphosphino)-2'-(2-naphthylmethoxy)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl; lithium acetate In dodecane; α,α,α-trifluorotoluene at 50℃; for 60h; Inert atmosphere;
Stage #2: In dichloromethane; trifluoroacetic acid optical yield given as %ee;
93%
Stage #1: tert-butyl trimethylsilyl methyl ketene acetal; 6-methoxynaphthalen-2-yl trifluoromethanesulfonate With (N,N,N',N'-tetramethylethylenediamine)dimethylpalladium(II); (R)-2-(dicyclohexylphosphino)-2'-(2-naphthylmethoxy)-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl; lithium acetate at 50℃; for 60h; Inert atmosphere;
Stage #2: With trifluoroacetic acid In dichloromethane at 25℃; for 4h;
93%
naproxol
26159-36-4

naproxol

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical; laccase from Trametes versicolor; oxygen In water; acetone at 20℃; for 168h; Enzymatic reaction;92%
With Iron(III) nitrate nonahydrate; 2,2,6,6-Tetramethyl-1-piperidinyloxy free radical; potassium chloride; oxygen In 1,2-dichloro-ethane at 25℃; Schlenk technique;90%
With chromium(VI) oxide; sulfuric acid In acetone at 0℃; for 0.5h;69%
(S)-6-methoxy-α-methyl-2-naphthaleneacetic acid ethyl ester
31220-35-6

(S)-6-methoxy-α-methyl-2-naphthaleneacetic acid ethyl ester

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With water; sodium hydroxide In 1,4-dioxane at 60℃; for 2h; pH=10 - 14;92%
With monoclonal antibody N116-27; tris hydrochloride; sodium chloride In acetonitrile at 37℃; pH=8.2; Enzyme kinetics;
Ru2 Cl4 [(-)-T-BINAP]2 (NEt3)

Ru2 Cl4 [(-)-T-BINAP]2 (NEt3)

2-(6-methoxynaphth-2-yl)acrylic acid
27602-79-5

2-(6-methoxynaphth-2-yl)acrylic acid

argon

argon

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
In methanol92%
(d,l)-2-(5-bromo-6-methoxy-2-naphthyl)propionic acid
27655-95-4

(d,l)-2-(5-bromo-6-methoxy-2-naphthyl)propionic acid

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With hydrogenchloride; aluminium trichloride In chloroform; water; toluene; 1,3,5-trimethyl-benzene91%
With hydrogenchloride; aluminium trichloride In chloroform; water; toluene; 1,3,5-trimethyl-benzene91%
(S)-phenethyl 2-(6-methoxynaphthalen-2-yl)propanoate
1181399-48-3

(S)-phenethyl 2-(6-methoxynaphthalen-2-yl)propanoate

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With palladium 10% on activated carbon; ammonium formate; palladium diacetate In methanol at 65℃; for 17h;91%
S-2-(6-methoxy-2-naphthyl)propionaldehyde
32305-59-2

S-2-(6-methoxy-2-naphthyl)propionaldehyde

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With sodium chlorite; sodium dihydrogenphosphate; 2-methyl-but-2-ene; tert.-butyl lithium In water; tert-butyl alcohol at 20℃; for 1h;91%
With sodium chlorite; disodium hydrogenphosphate; 2-methyl-but-2-ene In water; tert-butyl alcohol for 1h;90%
With sodium chlorite; potassium dihydrogenphosphate; 2-methyl-but-2-ene In water; tert-butyl alcohol at 20℃; for 20.8h;184.7 mg
(S)-naproxen methyl ester
26159-35-3

(S)-naproxen methyl ester

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With hydrogenchloride In water; acetic acid at 85℃;90%
Acid hydrolysis;
With sodium hydroxide for 3h; Heating;
With naproxen esterase(NP); water Enzymatic reaction;
(4R)-4-isopropyl-3-[(2S)-2-(6-methoxynaphth-2-yl)propionyl]oxazolidin-2-one

(4R)-4-isopropyl-3-[(2S)-2-(6-methoxynaphth-2-yl)propionyl]oxazolidin-2-one

A

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

B

(R)-4-isopropyloxazolidin-2-one
95530-58-8

(R)-4-isopropyloxazolidin-2-one

Conditions
ConditionsYield
With lithium hydroxide; dihydrogen peroxide In tetrahydrofuran; water at 20℃; for 12h;A 74%
B 90%
(4R,2'S)-3-[2'-(6-methoxy-naphthalen-2-yl)propionyl]-4-phenyl-oxazolidin-2-one
878194-08-2

(4R,2'S)-3-[2'-(6-methoxy-naphthalen-2-yl)propionyl]-4-phenyl-oxazolidin-2-one

A

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

B

(4R)-phenyl-2-oxazolidinone
90319-52-1

(4R)-phenyl-2-oxazolidinone

Conditions
ConditionsYield
Stage #1: (4R,2'S)-3-[2'-(6-methoxy-naphthalen-2-yl)propionyl]-4-phenyl-oxazolidin-2-one With lithium hydroxide monohydrate; dihydrogen peroxide In tetrahydrofuran; water at 20℃; for 12h; Inert atmosphere;
Stage #2: With hydrogenchloride In water pH=3; Inert atmosphere;
A 90%
B 89%
(2S,3R,4S)-2,3-Dihydroxy-4-(6-methoxynaphthalen-2-yl)-2-phenylpentane
301663-72-9

(2S,3R,4S)-2,3-Dihydroxy-4-(6-methoxynaphthalen-2-yl)-2-phenylpentane

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
Stage #1: (2S,3R,4S)-2,3-Dihydroxy-4-(6-methoxynaphthalen-2-yl)-2-phenylpentane With sodium periodate In dichloromethane for 1h; Oxidation; oxidative cleavage;
Stage #2: With jones reagent In acetone for 1h; Oxidation; Further stages.;
88%
(S)-2-(6-Methoxy-naphthalen-2-yl)-propionic acid (2R,3S,4S,5S)-2,3,4,5,6-pentahydroxy-hexyl ester

(S)-2-(6-Methoxy-naphthalen-2-yl)-propionic acid (2R,3S,4S,5S)-2,3,4,5,6-pentahydroxy-hexyl ester

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
Stage #1: (S)-2-(6-Methoxy-naphthalen-2-yl)-propionic acid (2R,3S,4S,5S)-2,3,4,5,6-pentahydroxy-hexyl ester With hydroxyl chlorite In methanol for 2h; Heating;
Stage #2: With sodium hydroxide In water
87%
(S)-4-tert-Butyl-3-[(S)-2-(6-methoxy-naphthalen-2-yl)-propionyl]-oxazolidin-2-one
197143-65-0

(S)-4-tert-Butyl-3-[(S)-2-(6-methoxy-naphthalen-2-yl)-propionyl]-oxazolidin-2-one

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

Conditions
ConditionsYield
With lithium hydroxide; dihydrogen peroxide In tetrahydrofuran at 25 - 30℃; for 1h;85.4%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

(S)-naproxen methyl ester
26159-35-3

(S)-naproxen methyl ester

Conditions
ConditionsYield
In diethyl ether100%
methanol
67-56-1

methanol

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

(S)-naproxen methyl ester
26159-35-3

(S)-naproxen methyl ester

Conditions
ConditionsYield
With sulfuric acid100%
With sulfuric acid for 4h;100%
With thionyl chloride at 20℃; for 16h; Cooling with ice; Inert atmosphere;99%
ethanol
64-17-5

ethanol

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

(S)-6-methoxy-α-methyl-2-naphthaleneacetic acid ethyl ester
31220-35-6

(S)-6-methoxy-α-methyl-2-naphthaleneacetic acid ethyl ester

Conditions
ConditionsYield
With sulfuric acid100%
With dmap; dicyclohexyl-carbodiimide In dichloromethane 1.) 0 deg C, 1 h, 2.) r.t., 6 h;91%
With sulfuric acid at 50℃; for 18h;84%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

S-(+)-2-(5-Bromo-6-Methoxy-2-Naphthyl)-Propionic Acid
84236-26-0

S-(+)-2-(5-Bromo-6-Methoxy-2-Naphthyl)-Propionic Acid

Conditions
ConditionsYield
With bromine In dichloromethane at 20℃; for 1h;100%
With aluminum tri-bromide; [bis(acetoxy)iodo]benzene In acetonitrile at 23℃;93%
Multi-step reaction with 4 steps
1: 53 percent / oxalyl chloride / toluene / 4 h / 90 °C
2: 85 percent / triethylamine / CH2Cl2 / 0.25 h / -10 °C
3: 85 percent / Br2 / 1,2-dichloro-ethane / 0.75 h / 0 °C
4: 95 percent / CH3COOH, concd. HCl, water / 85 °C
View Scheme
With sodium hypochlorite; potassium bromide In methanol; water
bromoacetic acid tert-butyl ester
5292-43-3

bromoacetic acid tert-butyl ester

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

((tert-butyl)oxycarbonyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate
646509-90-2

((tert-butyl)oxycarbonyl)methyl (2S)-2-(6-methoxy(2-naphthyl))propanoate

Conditions
ConditionsYield
With sodium hydrogencarbonate In N,N-dimethyl-formamide at 20℃; for 48h;100%
With sodium hydrogencarbonate In N,N-dimethyl-formamide at 20℃; for 48h;
memantine*
19982-08-2

memantine*

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

memantine-(S)-naproxen salt
1185878-08-3

memantine-(S)-naproxen salt

Conditions
ConditionsYield
In methanol at 20℃;100%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

(-)-tramadol

(-)-tramadol

(1S,2S)-2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol (S)-naproxen salt
1112063-73-6

(1S,2S)-2-((dimethylamino)methyl)-1-(3-methoxyphenyl)cyclohexanol (S)-naproxen salt

Conditions
ConditionsYield
In methanol at 20℃;100%
methanol
67-56-1

methanol

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

methyl 2-(6-methoxy-2-naphthyl)propionate
30012-51-2

methyl 2-(6-methoxy-2-naphthyl)propionate

Conditions
ConditionsYield
With sulfuric acid for 6h; Reflux;100%
With sulfuric acid for 18h; Reflux;98%
Stage #1: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid With sulfuryl dichloride In dichloromethane at 50℃; for 1h;
Stage #2: methanol With triethylamine In dichloromethane at 20℃;
93%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

glycine ethyl ester hydrochloride
5680-79-5

glycine ethyl ester hydrochloride

N-[2-(S)-(6-methoxy-2-naphthyl)propanoyl]glycine methyl ester
847454-70-0

N-[2-(S)-(6-methoxy-2-naphthyl)propanoyl]glycine methyl ester

Conditions
ConditionsYield
Stage #1: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid With 1,1'-carbonyldiimidazole In chloroform at 20℃; for 1h; Inert atmosphere;
Stage #2: glycine ethyl ester hydrochloride In chloroform Inert atmosphere;
100%
With 4-pyrrolidin-1-ylpyridine; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane at 0 - 20℃; Inert atmosphere;60%
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In acetonitrile for 3h;
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

cetyltrimethylammonium hydroxide
505-86-2

cetyltrimethylammonium hydroxide

cetyltrimethylammonium naproxenate

cetyltrimethylammonium naproxenate

Conditions
ConditionsYield
In propan-1-ol100%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

(S)-naproxen methyl ester
26159-35-3

(S)-naproxen methyl ester

Conditions
ConditionsYield
With sulfuric acid In methanol at 80℃; for 8h; stereoselective reaction;100%
With sulfuric acid In methanol at 20℃; for 12h; Inert atmosphere;88%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

C51H51NO8

C51H51NO8

C51H51NO8*C14H14O3

C51H51NO8*C14H14O3

Conditions
ConditionsYield
In acetone99.9%
10-Undecen-1-ol
112-43-6

10-Undecen-1-ol

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

(S)-naproxen undec-10-en-1-yl ester
142634-66-0

(S)-naproxen undec-10-en-1-yl ester

Conditions
ConditionsYield
toluene-4-sulfonic acid In benzene Heating;99%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

naproxol
26159-36-4

naproxol

Conditions
ConditionsYield
Stage #1: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃; for 0.5h;
Stage #2: With sodium tetrahydroborate; water In tetrahydrofuran at 0℃; for 0.5h;
99%
Stage #1: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid With lithium aluminium tetrahydride In tetrahydrofuran at 0 - 20℃; Inert atmosphere; Reflux;
Stage #2: With rochelle salt In tetrahydrofuran at 0℃; Inert atmosphere;
89%
With lithium aluminium tetrahydride In tetrahydrofuran at 20℃; for 16h;87%
methyl(2-hydroxyethyl)carbamic acid tert-butyl ester
57561-39-4

methyl(2-hydroxyethyl)carbamic acid tert-butyl ester

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

2-((tert-butoxy)-N-methylcarbonylamino)ethyl (2S)-2-(6-methoxy(2 naphthyl)) propanoate

2-((tert-butoxy)-N-methylcarbonylamino)ethyl (2S)-2-(6-methoxy(2 naphthyl)) propanoate

Conditions
ConditionsYield
With 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride; dmap In dichloromethane at 0 - 20℃; for 24h;99%
cholesterol
57-88-5

cholesterol

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

C41H58O3
1416973-03-9

C41H58O3

Conditions
ConditionsYield
Stage #1: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid With dicyclohexyl-carbodiimide In dichloromethane at 0℃; for 0.5h; Inert atmosphere;
Stage #2: cholesterol With dmap In dichloromethane at 0℃; for 8h;
99%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

2-diazopropane
2684-60-8

2-diazopropane

(S)-6-methoxy-α-methyl-2-naphthaleneacetic acid isopropyl ester

(S)-6-methoxy-α-methyl-2-naphthaleneacetic acid isopropyl ester

Conditions
ConditionsYield
In dichloromethane at 19℃; for 2h; chemoselective reaction;99%
2,2'-dimethyl-[1,1'-biphenyl]iodonium trifluoromethanesulfonate salt

2,2'-dimethyl-[1,1'-biphenyl]iodonium trifluoromethanesulfonate salt

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

C28H25IO3

C28H25IO3

Conditions
ConditionsYield
With copper diacetate; sodium carbonate; (3aR,3a'R,8aS,8a'S)-2,2'-(propane-2,2-diyl)bis(8,8a-dihydro-3aH-indeno[1,2-d]oxazole) In dichloromethane; water at 30℃; for 12h; enantioselective reaction;99%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

L-valine isopropyl ester hydrochloride

L-valine isopropyl ester hydrochloride

L-valine isopropyl ester naproxenate

L-valine isopropyl ester naproxenate

Conditions
ConditionsYield
Stage #1: L-valine isopropyl ester hydrochloride With ammonium hydroxide In water
Stage #2: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid In chloroform at 20℃; for 0.333333h;
98.5%
C19H42N(1+)*C4H9O(1-)

C19H42N(1+)*C4H9O(1-)

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

cetyltrimethylammonium naproxenate

cetyltrimethylammonium naproxenate

Conditions
ConditionsYield
In methanol98.3%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

(S)-2-(1-chloro-2-methoxynaphthalen-6-yl)propanoic acid
89617-86-7

(S)-2-(1-chloro-2-methoxynaphthalen-6-yl)propanoic acid

Conditions
ConditionsYield
With N-chloro-succinimide; dimethyl sulfoxide In chloroform at 25℃; for 12h; Reagent/catalyst; Schlenk technique;98%
With sulfuryl dichloride at 20℃; for 1h;89%
Multi-step reaction with 3 steps
1: 100 percent / diethyl ether
2: 80 percent / sodium hypochlorite, aq. HCl / CH2Cl2 / 1 h / 15 °C
3: 37percent aq. Hcl / acetone / 3 h / Heating
View Scheme
With sodium hypochlorite In methanol; water
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

(2R)-(-)-2-phenyl-2-(piperidin-1-yl)ethanol
154472-05-6

(2R)-(-)-2-phenyl-2-(piperidin-1-yl)ethanol

(2S)-(S)-1-phenyl-2-(piperidin-1-yl)ethyl 2-(2-methoxynaphthalen-6-yl)propanoate

(2S)-(S)-1-phenyl-2-(piperidin-1-yl)ethyl 2-(2-methoxynaphthalen-6-yl)propanoate

Conditions
ConditionsYield
Stage #1: (2R)-(-)-2-phenyl-2-(piperidin-1-yl)ethanol With methanesulfonyl chloride; triethylamine In chloroform at 0 - 5℃; for 0.5h;
Stage #2: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid With triethylamine In chloroform at 5 - 20℃; for 16h; enantiospecific reaction;
98%
(2S)-2-(6-methoxy(2-naphthyl))propanoic acid
22204-53-1

(2S)-2-(6-methoxy(2-naphthyl))propanoic acid

(2R)-7-(nitrooxy)-4,8-dioxabicyclo(3.3.0)oct-2-yl(2S)-2-(6-methoxy (2-naphthyl)) propanoate
646509-45-7

(2R)-7-(nitrooxy)-4,8-dioxabicyclo(3.3.0)oct-2-yl(2S)-2-(6-methoxy (2-naphthyl)) propanoate

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;97.6%

22204-53-1Relevant articles and documents

Asymmetric Synthesis of (S)-2-(6-methoxy-2-naphthyl)propanoic Acid

Hiyama, Tamejiro,Saito, Kumi,Sato, Ken-ichi,Wakasa, Noriko,Inoue, Masuo

, p. 1471 - 1472 (1986)

For the synthesis of the title compound of 60 percent ee, a new method is established which involves cyanation of an acetal derived from 1-(6-methoxy-2-naphthyl)ethanone and (S,S)-2,4-pentanediol, alkaline hydrolysis, and finally hydrogenolysis with palladium catalyst.

Disposition of naproxen, naproxen acyl glucuronide and its rearrangement isomers in the isolated perfused rat liver

Lo,Addison,Hooper,Dickinson

, p. 309 - 319 (2001)

1. An isolated perfused rat liver (IPRL) preparation was used to investigate separately the disposition of the non-steroidal anti-inflammatory drug (NSAID) naproxen (NAP), its reactive acyl glucuronide metabolite (NAG) and a mixture of NAG rearrangement isomers (isoNAG), each at 30 μg NAP equivalents ml-1 perfusate (n = 4 each group). 2. Following administration to the IPRL, NAP was eliminated slowly in a log-linear manner with an apparent elimination half-life (t1/2) of 13.4 ± 4.4 h. No metabolites were detected in perfusate, while NAG was the only metabolite present in bile in measurable amounts (3.9 ± 0.8% of the dose). Following their administration to the IPRL, both NAG and isoNAG were rapidly hydrolysed (t1/2 in perfusate = 57 ± 3 and 75 ± 14 min respectively). NAG also rearranged to isoNAG in the perfusate. Both NAG and isoNAG were excreted intact in bile (24.6 and 14.8% of the NAG and isoNAG doses, respectively). 3. Covalent NAP-protein adducts in the liver increased as the dose changed from NAP to NAG to isoNAG (0.20 to 0.34 to 0.48% of the doses, respectively). Similarly, formation of covalent NAP-protein adducts in perfusate were greater in isoNAG-dosed perfusions. The comparative results suggest that isoNAG is a better substrate for adduct formation with liver proteins than NAG.

New synthesis of optically active α-arylpropanoic acid: The asymmetric hydrogenation of atropic acid over cinchona-modified Pd/Fe2O3 catalysts

Ma,Wang,Shi

, p. 175 - 182 (2003)

The first satisfactory application of the heterogeneous cinchona-modified Pd/Fe2O3 catalyst system in the synthesis of optically active α-arylpropanoic acid, namely, the highly enantioselective (up to 87% ee) hydrogenation of atropic acid to S-(+)-naproxen is described.

Fabrication of a nano-drug delivery system based on layered rare-earth hydroxides integrating drug-loading and fluorescence properties

Gu, Qingyang,Chen, Wen,Duan, Fei,Ju, Ruijun

, p. 12137 - 12143 (2016)

We demonstrate the first example of intercalation of naproxen (abbr. NPX) into layered europium hydroxide (LEuH) and investigate the structure, chemical composition, thermostability, morphology, luminescence properties, cytotoxic effect, and controlled-release behaviors. Different deprotonation degrees lead to NPX-LEuH composites with diverse structures (horizontal or vertical arrangement), and the thermal stability of organics is enhanced after intercalation. The Eu3+ luminescence in NPX-LEuH composites is enhanced, especially for the NPX-LEuH-1: 0.5 composite. The content of naproxen in the intercalation material can be confirmed by HPLC. The cytotoxic effect of LEuH is observed with a sulforhodamine B (SRB) colorimetric assay, which reveals that the LEuH has low cytotoxic effects on most cells. In addition, the NPX-LEuH nanocomposites can control the release of NPX in Na2HPO4-NaH2PO4 buffer solution at pH 6.86 and 37 °C, and the complete release needs about 200 min. The release mechanism can be ascribed to the ion-exchange reaction between NPX and HPO42-/H2PO4- in bulk solution. The ion-exchange velocity is fast at the beginning and slows down gradually with the exchange reaction. The construction of LRH composites with drug molecules provides a beneficial pathway for preparing a nano-drug delivery system based on LRHs integrating drug-loading and fluorescence properties.

Asymmetric dihydroxylation in an approach to the enantioselective synthesis of 2-arylpropanoic acid non-steroidal anti-inflammatory drugs

Griesbach, Robert C.,Hamon, David P. G.,Kennedy, Rebecca J.

, p. 507 - 510 (1997)

Naproxen ((S)-2-(6-methoxy-2-naphthyl)propanoic acid) and flurbiprofen ((S)2-3 -fluoro-4-phenylphenyl) propanoic acid) have been synthesised in high en antiomeric excess. The synthetic strategy employed waste introduce asymmetry into the molecules by Sharpless asymmetric dihydroxylation of the appropriate methyl styrenes. The resultant diols were then converted into optically active epoxides and the required stereogenic centre was assembled by catalytic hydrogenolysis of the introduced benzylic epoxide oxygen bond, followed by oxidation of the derived optically active primary alcohol.

Preparation of One-Pot Immobilized Lipase with Fe3O4 Nanoparticles Into Metal-Organic Framework For Enantioselective Hydrolysis of (R,S)-Naproxen Methyl Ester

Ozyilmaz, Elif,Ascioglu, Sebahat,Yilmaz, Mustafa

, p. 3687 - 3694 (2021)

Immobilization of enzyme to magnetic metal-organic frameworks (MOF) can preserve biological functionality in harsh environments to increase enzymes activity, stability, and improve reusability. The magnetic Fe3O4 nanoparticles were treated with calix[4]arene tetracarboxylic acid (Calix) and Candida rugosa lipase (CRL), and then encapsulated into the zeolitic imidazole framework-8 (Fe3O4@Calix-ZIF-8@CRL). The lipase activity data of Fe3O4@Calix-ZIF-8@CRL was 2.88 times higher than that of the Fe3O4@ZIF-8@CRL (without Calix). The catalytic properties of immobilized lipases were studied on the enantioselective hydrolysis of R/S-naproxen methyl ester. It was also observed that Fe3O4@Calix-ZIF-8@CRL has excellent enantioselectivity (E=371) compared to Fe3O4@ZIF-8@CRL (E=131). Furthermore, Fe3O4@Calix-ZIF-8@CRL was seen to still retain 30 % of the conversion rate after the fifth reuse. This work may also be useful for the pharmaceutical industry due to the increased reusability and stability of enzymes, the enantiomeric selectivity exhibited by MOF-enzyme biocomposites, and the significant differences in the biological activities of the enantiomers.

Scalable synthesis of a new enantiomerically pure π-extended rigid amino indanol

Rendina, Victor L.,Goetz, Samantha A.,Neitzel, Angelika E.,Kaplan, Hilan Z.,Kingsbury, Jason S.

, p. 15 - 18 (2012)

A convenient route to a benzo-fused amino indanol chiral controller is disclosed. The synthesis is based on a newly optimized entry to 3H-benz(e)indene that can be performed on decagram scale with no purification of intermediates. Subsequent oxidation, classical resolution, and Ritter steps give the target synthon in >98% ee. The resolution features (S)-naproxen as an inexpensive and highly crystalline resolving agent. Conversion of the amino alcohol to its bis(oxazolinyl)-propane is also reported. A solid state structure of the CuCl2-box complex shows preservation of the distorted square planar geometry found in the parent CuCl2(indanyl-box) despite greater steric crowding by the blocking groups.

Asymmetric synthesis of acids by the palladium-catalyzed hydrocarboxylation of olefins in the presence of (R)-(-)- or (S)-(+)-1,1′-binaphthyl-2,2′-diyl hydrogen phosphate

Alper, Howard,Hamel, Nathalie

, p. 2803 - 2804 (1990)

-

Enantioselective synthesis of (S)-naproxen using immobilized lipase on chitosan beads

Gilani, Saeedeh L.,Najafpour, Ghasem D.,Heydarzadeh, Hamid D.,Moghadamnia, Aliakbar

, p. 304 - 314 (2017)

S-naproxen by enantioselective hydrolysis of racemic naproxen methyl ester was produced using immobilized lipase. The lipase enzyme was immobilized on chitosan beads, activated chitosan beads by glutaraldehyde, and Amberlite XAD7. In order to find an appropriate support for the hydrolysis reaction of racemic naproxen methyl ester, the conversion and enantioselectivity for all carriers were compared. In addition, effects of the volumetric ratio of two phases in different organic solvents, addition of cosolvent and surfactant, optimum pH and temperature, reusability, and inhibitory effect of methanol were investigated. The optimum volumetric ratio of two phases was defined as 3:2 of aqueous phase to organic phase. Various water miscible and water immiscible solvents were examined. Finally, isooctane was chosen as an organic solvent, while 2-ethoxyethanol was added as a cosolvent in the organic phase of the reaction mixture. The optimum reaction conditions were determined to be 35?°C, pH?7, and 24?h. Addition of Tween-80 in the organic phase increased the accessibility of immobilized enzyme to the reactant. The optimum organic phase compositions using a volumetric ratio of 2-ethoxyethanol, isooctane and Tween-80 were 3:7 and 0.1% (v/v/v), respectively. The best conversion and enantioselectivity of immobilized enzyme using chitosan beads activated by glutaraldehyde were 0.45 and 185, respectively.

Metal-based scaffolds of Schiff bases derived from naproxen: Synthesis, antibacterial activities, and molecular docking studies

Shaheen, Muhammad Ashraf,Feng, Shanshan,Anthony, Mehwish,Tahir, Muhammad Nawaz,Hassan, Mubashir,Seo, Sung-Yum,Ahmad, Saeed,Iqbal, Mudassir,Saleem, Muhammad,Lu, Changrui

, (2019)

We report here the synthesis, characterization, and antibacterial evaluation of transition metal complexes of Ni, Cu, Co, Mn, Zn, and Cd (6a–f), using a Schiff base ligand (5) derived from naproxen (an anti-inflammatory drug) and 5-bromosalicylaldehyde by a series of reactions. The ligand and the synthesized complexes were characterized by elemental analysis, UV-Visible, FTIR, and XRD techniques. The ligand 5 behaves as a bidentate donor and coordinates with metals in square planar or tetrahedral fashion. In order to evaluate its bioactivity profile, we screened the Schiff base ligand and its metal complexes (6a–f) against different species of bacteria and the complexes were found to exhibit significant antibacterial activity. The complexes showed more potency against Bacillus subtilis as compared to the other species. Moreover, we modeled these complexes’ binding affinity against COX1 protein using computational docking.

Improvement of catalytic activity of lipase in the presence of wide rim substituted calix[4]arene carboxylic acid-grafted magnetic nanoparticles

Akceylan, Ezgi,Sahin, Ozlem,Yilmaz, Mustafa

, p. 113 - 123 (2014)

Candida rugosa lipase immobilized on calix[4]arene carboxylic acid-grafted magnetic nanoparticles using a sol-gel encapsulation technique was tested for activity, which was assessed both in the enantioselective hydrolysis of racemic Naproxen methyl ester and that of p-nitrophenylpalmitate. It has also been noticed that, compared to the free enzyme (E = 137) with an ee value of [98 %, S-Naproxen calix[4]arene carboxylic acid-grafted magnetic nanoparticles based on encapsulated lipase (Calix-1-MN and Calix-2-MN) offer excellent enantioselectivity (E = 373 and E = 381). Moreover, the results indicated that after the fifth reuse in the enantioselective reaction, the encapsulated lipase (Calix-2-MN) still retained about 43 % of its conversion power. Springer Science+Business Media Dordrecht 2013.

Highly effective soluble polymer-supported catalysts for asymmetric hydrogenation [2]

Fan, Qing-Hua,Ren, Chang-Yu,Yeung, Chi-Hung,Hu, Wen-Hao,Chan, Albert S. C.

, p. 7407 - 7408 (1999)

-

Asymmetric transformation of the second kind of racemic naproxen

Lopez, Francisco J.,Ferrino, Sergio A.,Reyes, Mario S.,Roman, Ruth

, p. 2497 - 2500 (1997)

Several chiral derivatives of racemic naproxen were subjected to asymmetric transformations. Notably, asymmetric transformation of the second kind of a mixture of 2b and 3b gave a diastereomeric excess (d.e.) over 90% in favor of 2b. This d.e. was increased to over 99% after recrystallization.

Reactive immunization strategy generates antibodies with high catalytic proficiencies

Lo,Wentworth P.,Jung,Yoon,Ashley,Janda

, p. 10251 - 10252 (1997)

-

Synthesis of diastereomeric anhydrides of (RS)-ketorolac and (RS)-etodolac, semi-preparative HPLC enantioseparation, establishment of molecular asymmetry and recovery of pure enantiomers

Malik, Poonam,Bhushan, Ravi

, p. 13681 - 13691 (2017)

Herein, enantioseparation of two anti-inflammatory drugs, namely, (RS)-ketorolac and (RS)-etodolac, commonly marketed and administered as racemates, was achieved by RP-HPLC. This method provided very low limit of detection values (3.69 and 3.02 ng mL-1 for diastereomeric derivatives of (R)- and (S)-Ket, respectively) as compared to those reported in literature. (S)-Naproxen benzotriazole ester, which was used as a chiral reagent, was synthesized and characterized by UV, IR, and 1H NMR spectroscopies, elemental analysis, and polarimetry. The diastereomeric derivatives were synthesized via microwave irradiation, separated on an analytical scale by RP-HPLC, and then isolated by preparative HPLC. The use of a mobile phase containing methanol and aqueous triethylamine phosphate (TEAP) in the isocratic mode was found to be successful for the separation of diastereomeric derivatives, and the separation conditions with respect to pH, flow rate, and buffer concentration were optimized. The diastereomeric derivatives were characterized, and their absolute configuration was established. Hydrolysis of the derivatives provided native enantiomers under mild reaction conditions. This study describes the successful enantioseparation of the above mentioned two analytes by semi-preparative HPLC with easy recovery of the native enantiomers without racemization and with the establishment of molecular asymmetry.

In vitro regioselective stability of β-1-O- and 2-O-acyl glucuronides of naproxen and their covalent binding to human serum albumin

Iwaki, Masahiro,Ogiso, Taro,Inagawa, Shinako,Kakehi, Kazuaki

, p. 52 - 57 (1999)

β-1-O- (NAG) and 2-O-glucuronides (2-isomer) of (S)-naproxen (NA) were prepared to determine which positional isomer(s) of the acyl glucuronide of NA is responsible for forming covalent adducts with human serum albumin (HSA). Their comparative stability and covalent binding adduct formation with HSA were investigated at pH 7.4 and at 37 °C. NA and its acyl glucuronides were simultaneously determined by HPLC. Three positional isomers were formed successively after incubation of NAG in the buffer only. However, when NAG was incubated with HSA (30 mg/mL), isomers other than the 2-isomer were formed in little or negligible quantities. In HSA solution, NAG (k(d) = 2.08 ± 0.08 h-1) was four times less stable than 2-isomer (k(d) 0.51 ± 0.02 h-1). NAG was degraded by hydrolysis (k(hyd) = 1.01 ± 0.10 h-1) and isomerization (k(iso) 1.07 ± 0.07 h-1) to the same extent; however, hydrolysis was predominant for the 2-isomer (k(d) = 0.51 ± 0.02 h-1). The incubation of both NAG and 2-isomer with HSA led to the formation of a covalent adduct; however, the adduct formation from the 2-isomer proceeded more slowly than that from NAG. The present results suggest that the covalent binding of NA to HSA via its acyl glucuronides proceeds through both transacylation (direct nucleophilic displacement) and glycation mechanisms; NAG rapidly forms an adduct that may be unstable, and the protein adduct from the 2-O-acyl glucuronide is as important for the covalent binding as those from the 1-O-acyl glucuronides.

Asymmetric Synthesis of Naproxen by a New Heterogeneous Catalyst

Wan, Kam T.,Davis, Mark E.

, p. 25 - 30 (1995)

A new heterogeneous, asymmetric catalyst is described.The catalyst is a modified version of the supported aqueous-phase catalyst reported previously (Wan and Davis, J.Catal. 148,1(1994)); ethylene glycol is used in place of water as the hydrophilic phase.Both the enantioselectivity and the activity of this new heterogeneous catalyst are comparable to the homogeneous analogue in neat methanol (or ethylene glycol); e.e.'s are 95.7percent vs 96.1percent and t.o.f.'s are 40.7 hr-1 vs 131.0 hr-1, respectively.Recycling of the catalyst is possible without leaching of ruthenium at a detection limit of 32 ppb.

Design and synthesis of Janus-type chiral dendritic diphosphanes and their applications in asymmetric hydrogenation

Liu, Ji,Feng, Yu,Ma, Baode,He, Yan-Mei,Fan, Qing-Hua

, p. 6737 - 6744 (2012)

A series of chiral diphosphane-functionalized Janus dendrimers (up to 16 BINAP units) have been readily synthesized by using liquid-phase organic synthesis with the third-generation Frechet-type poly(aryl ether) dendron as the soluble support. The resulting dendritic ligands were purified by simple solvent precipitation without the need for chromatographic separation at the end of reaction. Complete functionalization of the dendrimers with BINAP moieties was confirmed by 1H NMR, MALDI-TOF mass spectroscopy, and elemental analyses. Their ruthenium complexes were applied to the asymmetric hydrogenation of 2-arylacrylic acids. It was found that only slightly lower enantioselectivities were achieved than the corresponding small-molecular Ru catalyst. Interestingly, a clear increase in activity of the dendritic catalysts was observed on going to the higher generations. In addition, the third-generation catalyst could be recycled without significant loss of catalytic activity or enantioselectivity before the fifth catalytic run. A new kind of easily available Janus dendritic diphosphane ligand has been synthesized and their metal complexes were applied to the asymmetric hydrogenation of 2-arylacrylic acids. Interestingly, a clear increase in activity of the dendritic catalysts was observed on going to the higher generations. Furthermore, the third-generation catalyst could be recycled at least five times. Copyright

An Investigation of the Palladium-Catalyzed, Formate-Mediated Hydroxycarbonylation of optically active 1-Arylethyl Esters

Baird, Jeff M.,Kern, John R.,Lee, Gary R.,Morgans, David J.,Sparacino, Mark, L.

, p. 1928 - 1933 (1991)

-

Synthesis, comparative docking, and pharmacological activity of naproxen amino acid derivatives as possible anti-inflammatory and analgesic agents

Elhenawy, Ahmed A.,Al-Harbi,Moustafa, Gaber O.,El-Gazzar,Abdel-Rahman, Rehab F.,Salim, Abd Elhamid

, p. 1773 - 1790 (2019)

Background and aim: Naproxen is a member of the Nonsteroidal anti-inflammatory drugs (NSAIDs). This work aimed to synthesize a safe NSAID agent based on a peptide derivative. Methods: The structure of compounds 5–20 was established on the basis of spectral data. Frontier molecular orbitals and chemical reactivity were discussed to clarify inter-and intramolecular interactions among tested compounds. We applied competitive molecular docking using polynomial logarithms to identify the most accurate algorithm for pharmacological activity prediction for the tested compounds. The docking protocol with the lowest RMSD was selected for analyzing binding affinity. Results: Docking results illustrated that the binding interaction increased after introduction of an acidic fragment to the parent compound. These compounds were selected for additional study against adsorption, distribution, metabolism, excretion, and toxicity (ADMET) in silico. The compounds tested had good oral bioavailability without any carcinogenesis effect; no marked health effects were observed via rodent toxicity. Compounds passed through docking and ADMET profiles for them (5–16) were examined as anti-inflammatory and analgesic agents. Compounds 8 and 16 showed higher anti-inflammatory potency than the reference drug and tested compounds. Compounds 8, 10, and 14 exhibited the highest analgesic potency compared to the other tested compounds. Conclusion: The tested compounds have shown negligible ulcerogenic effects, and may be considered safer drugs than naproxen for treating inflammatory conditions.

Asymmetric hydrogenation of 2-arylacrylic acids catalyzed by immobilized Rn-BINAP complex in 1-n-butyl-3-methylimidazolium tetrafluoroborate molten salt

Monteiro, Adriano L.,Zinn, Fabiano K.,De Souza, Roberto F.,Dupont, Jairton

, p. 177 - 179 (1997)

The [RuCl2-(S)-BINAP]2.NEt3 catalyst precursor dissolved in 1-n-butyl-3-methylimidazolium tetrafluoroborate molten salt is able-to hydrogenate 2-arylacrylic acids (aryl=Ph or 6-MeO-naphthyl) with enantioselectivities similar or higher than those obtained in homogeneous media. Moreover, the hydrogenated products can be quantitatively separated from the reaction mixture and the recovered ionic liquid catalyst solution can be reused several times without any significant changes in the catalytic activity or selectivity.

Reshaping the active pocket of esterase Est816 for resolution of economically important racemates

Fan, Xinjiong,Fu, Yao,Liu, Xiaolong,Zhao, Meng

, p. 6126 - 6133 (2021/09/28)

Bacterial esterases are potential biocatalysts for the production of optically pure compounds. However, the substrate promiscuity and chiral selectivity of esterases usually have a negative correlation, which limits their commercial value. Herein, an efficient and versatile esterase (Est816) was identified as a promising catalyst for the hydrolysis of a wide range of economically important substrates with low enantioselectivity. We rationally designed several variants with up to 11-fold increased catalytic efficiency towards ethyl 2-arylpropionates, mostly retaining the initial substrate scope and enantioselectivity. These variants provided a dramatic increase in efficiency for biocatalytic applications. Based on the best variant Est816-M1, several variants with higher or inverted enantioselectivity were designed through careful analysis of the structural information and molecular docking. Two stereoselectively complementary mutants, Est816-M3 and Est816-M4, successfully overcame and even reversed the low enantioselectivity, and several 2-arylpropionic acid derivatives with highEvalues were obtained. Our results offer potential industrial biocatalysts for the preparation of structurally diverse chiral carboxylic acids and further lay the foundation for improving the catalytic efficiency and enantioselectivity of esterases.

PHOTOLYTIC COMPOUNDS AND TRIPLET-TRIPLET ANNIHILATION MEDIATED PHOTOLYSIS

-

Paragraph 0026, (2021/04/17)

The invention provides novel photolytic compounds and prodrugs, nanoparticles and compositions thereof, and methods of conducting photolysis mediated by triplet-triplet annihilation.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 22204-53-1